Safety and Efficacy of Bevacizumab With SOC In Patients With Advanced NSCLC

Synopsis Around 80% to 85% of lung cancers are cases of non-small cell lung cancer (NSCLC). NSCLC is considered to be one of the fatal forms of lung cancer. Treatment in patients with NSCLC can be difficult. Bevacizumab therapy in advanced NSCLC has suggested a survival benefit in many trials. This “ JOURNAL WATCH ” discusses the study “Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients with Advanced Non-Small Cell Lung Cancer”, from JAMA Oncology, Dec 2018.

Authors: Cesare Gridelli et al. What was the need for this study? Bevacizumab treatment has been previously investigated in colorectal and breast cancers. However, its safety and efficacy in NSCLC are not well-defined. This is the first phase-3 randomized clinical trial on bevacizumab across various lines of treatment in patients with advanced non-small-cell lung cancer…